Literature DB >> 23674211

Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on ¹⁸F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma.

Choon-Young Kim1, Chae Moon Hong, Do-Hoon Kim, Seung Hyun Son, Shin Young Jeong, Sang-Woo Lee, Jaetae Lee, Byeong-Cheol Ahn.   

Abstract

PURPOSE: The aim of this study was to determine whether maximum standardized uptake value (SUVmax), whole-body metabolic tumour volume (WBMTV), and whole-body total lesion glycolysis (WBTLG) measured on pretreatment ¹⁸F-FDG PET/CT can predict prognosis in patients with extranodal natural killer/T-cell lymphoma (ENKTL).
METHODS: We conducted a retrospective analysis of 20 patients with newly-diagnosed ENKTL who underwent pretreatment ¹⁸F-FDG PET/CT. WBMTV and WBTLG were measured automatically using the boundaries of voxels presenting SUV>3.0. Uni- and multivariate analyses for survival and disease progression were performed using clinical variables and PET parameters (SUVmax, WBMTV, and WBTLG).
RESULTS: During the follow-up period (median 26.3 months), 12 patients showed disease progression and 10 patients died from the disease. Receiver operating characteristic curve analysis showed cut-off values for SUVmax, WBMTV and WBTLG of 8.1, 14.4 cm³ and 52.7, respectively. Univariate analysis showed that the International Prognostic Index (IPI) score and PET parameters were significant predictors of overall survival (OS) and progression-free survival (PFS). Multivariate analysis, even after adjustment for the IPI score, showed that high WBMTV was the best predictor of OS and PFS, and high SUVmax and WBTLG were significant predictors of PFS.
CONCLUSION: Our results suggested that the use of PET parameters together with the IPI score may be useful for detailed prediction of prognosis in ENKTL patients. Therefore, despite a lower IPI score, patients with high PET parameter values might be considered candidates for aggressive therapy to improve clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23674211     DOI: 10.1007/s00259-013-2443-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  24 in total

1.  Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer.

Authors:  Jong-Ryool Oh; Ji-Hyoung Seo; Ari Chong; Jung-Joon Min; Ho-Chun Song; Young-Chul Kim; Hee-Seung Bom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-21       Impact factor: 9.236

2.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

3.  18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma.

Authors:  Remy Lim; Anne Eaton; Nancy Y Lee; Jeremy Setton; Nisha Ohri; Shyam Rao; Richard Wong; Matthew Fury; Heiko Schöder
Journal:  J Nucl Med       Date:  2012-08-14       Impact factor: 10.057

4.  A novel prognostic model for extranodal natural killer/T-cell lymphoma.

Authors:  Jia-Jia Huang; Ying-Jie Zhu; Yi Xia; Wei Zhao; Tong-Yu Lin; Wen-Qi Jiang; Hui-Qiang Huang; Zhi-Ming Li
Journal:  Med Oncol       Date:  2011-07-23       Impact factor: 3.064

5.  Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis.

Authors:  Steven M. Larson; Yusuf Erdi; Timothy Akhurst; Madhu Mazumdar; Homer A. Macapinlac; Ronald D. Finn; Cecille Casilla; Melissa Fazzari; Neil Srivastava; Henry W.D. Yeung; John L. Humm; Jose Guillem; Robert Downey; Martin Karpeh; Alfred E. Cohen; Robert Ginsberg
Journal:  Clin Positron Imaging       Date:  1999-05

Review 6.  The 2008 WHO classification of lymphomas: implications for clinical practice and translational research.

Authors:  Elaine S Jaffe
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

7.  Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index.

Authors:  Chor-Sang Chim; Shing-Yan Ma; Wing-Yan Au; Carolyn Choy; Albert K W Lie; Raymond Liang; Chun-Chung Yau; Yok-Lam Kwong
Journal:  Blood       Date:  2003-08-21       Impact factor: 22.113

Review 8.  Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment.

Authors:  Holbrook Kohrt; Ranjana Advani
Journal:  Leuk Lymphoma       Date:  2009-11

9.  Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells.

Authors:  M Yamaguchi; K Kita; H Miwa; K Nishii; K Oka; T Ohno; S Shirakawa; M Fukumoto
Journal:  Cancer       Date:  1995-12-01       Impact factor: 6.860

10.  Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement.

Authors:  Moo-Kon Song; Joo-Seop Chung; Ho-Jin Shin; Sang-Min Lee; Su-Ee Lee; Ho-Sup Lee; Gyeong-Won Lee; Seong-Jang Kim; Seok-Mo Lee; Dong-Seop Chung
Journal:  Ann Hematol       Date:  2011-11-11       Impact factor: 3.673

View more
  32 in total

1.  Prognostic relevance of pretransplant Deauville score on PET-CT and presence of EBV DNA in patients who underwent autologous stem cell transplantation for ENKTL.

Authors:  S H Lim; S H Hyun; H S Kim; J Y Lee; K H Yoo; K S Jung; H-N Song; J Cho; S Park; Y H Ko; S J Kim; J Y Choi; W S Kim
Journal:  Bone Marrow Transplant       Date:  2016-02-08       Impact factor: 5.483

2.  Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume.

Authors:  Luca Ceriani; Lisa Milan; Peter W M Johnson; Maurizio Martelli; Stefano Presilla; Luca Giovanella; Emanuele Zucca
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-02-26       Impact factor: 9.236

3.  Predictive value of 18F-FDG PET/CT in adults with T-cell lymphoblastic lymphoma: post hoc analysis of results from the GRAALL-LYSA LLO3 trial.

Authors:  Stéphanie Becker; Thomas Vermeulin; Anne-Ségolène Cottereau; Nicolas Boissel; Pierre Vera; Stéphane Lepretre
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-21       Impact factor: 9.236

4.  Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of 68Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer.

Authors:  Qiong Zou; Ju Jiao; Min-Hong Zou; Ming-Zhao Li; Ting Yang; Lei Xu; Yong Zhang
Journal:  Abdom Radiol (NY)       Date:  2020-09-18

5.  Management of advanced NK/T-cell lymphoma.

Authors:  Eric Tse; Yok-Lam Kwong
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

6.  Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT.

Authors:  Eric M Rohren; Elba C Etchebehere; John C Araujo; Brian P Hobbs; Nancy M Swanston; Michael Everding; Tracy Moody; Homer A Macapinlac
Journal:  J Nucl Med       Date:  2015-07-01       Impact factor: 10.057

7.  Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?

Authors:  Laura Evangelista; Anna Rita Cervino; Cristina Ghiotto; Tania Saibene; Silvia Michieletto; Bozza Fernando; Enrico Orvieto; Valentina Guarneri; Pierfranco Conte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-31       Impact factor: 9.236

8.  Metabolic parameters using ¹⁸F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma.

Authors:  Do-Hoon Kim; Bong-Il Song; Chae Moon Hong; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-03       Impact factor: 9.236

9.  SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model.

Authors:  Luca Ceriani; Giuseppe Gritti; Luciano Cascione; Maria Cristina Pirosa; Angela Polino; Teresa Ruberto; Anastasios Stathis; Andrea Bruno; Alden A Moccia; Luca Giovanella; Stefanie Hayoz; Sämi Schär; Stefan Dirnhofer; Alessandro Rambaldi; Giovanni Martinelli; Christoph Mamot; Emanuele Zucca
Journal:  Blood Adv       Date:  2020-03-24

10.  Evaluating the Predictive Ability of Initial Staging F-18 FDG PET/CT for the Prognosis of Non-Hodgkin Malignant Lymphoma Patients Who Underwent Stem Cell Transplantation.

Authors:  Yun Soo Park; Seok Mo Lee; Ji Sun Park; Sang Kyun Bae; Hye-Kyung Shim; Won-Sik Lee; Sang-Min Lee
Journal:  Nucl Med Mol Imaging       Date:  2017-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.